©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 7, 2014; 20(37): 13343-13368
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13343
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13343
Table 6 Ongoing clinical trials of gene therapy in pancreatic cancer
| Phase | Transgenes |
| I | Oncolytic adenovirus and oncolytic herpesvirus1 |
| Somatostatin receptor 2 (sst2), Deoxycitidine kinase :: uridylmonophosphate kinase (dck::umk) | |
| Somatostatin receptor 2 (sst2) | |
| Mesothelin-scFv with signaling domains comprised of TCR , CD28, and 4-1BB (CD137) cDNA | |
| GM-CSF | |
| PANVAC (CEA, MUC-1, and TRICOM) | |
| Cytosine deaminase, Herpes simplex virus thymidine kinase (HSV-TK) | |
| Cyclin G1 | |
| p53 | |
| BikDD (DOTAP-cholesterol mediated gene transfection) | |
| Mutated Ras | |
| I/II | Cytochrome p450 |
| AEG 35156: antisense oligonucleotide to X-linked inhibitor of apoptosis protein (XIAP) | |
| Herpes simplex virus thymidine kinase (HSV-TK) | |
| Diphtheria Toxin A Chain (DTA) gene with H19 promoter | |
| Alpha-(1,3) galactosyltransferase | |
| II | CEA, MUC-1, and PANVAC |
| Mutated Ras | |
| Alpha-(1,3) galactosyltransferase | |
| III | Alpha-(1,3) galactosyltransferase |
| PANVAC (CEA, MUC-1, and TRICOM)2 |
- Citation: Liu SX, Xia ZS, Zhong YQ. Gene therapy in pancreatic cancer. World J Gastroenterol 2014; 20(37): 13343-13368
- URL: https://www.wjgnet.com/1007-9327/full/v20/i37/13343.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i37.13343